Market closed
Glaukos/$GKOS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Glaukos
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Ticker
$GKOS
Sector
Trading on
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
907
Website
Glaukos Metrics
BasicAdvanced
$7.8B
Market cap
-
P/E ratio
-$2.93
EPS
1.03
Beta
-
Dividend rate
Price and volume
Market cap
$7.8B
Beta
1.03
52-week high
$143.20
52-week low
$59.22
Average daily volume
557K
Financial strength
Current ratio
5.542
Quick ratio
4.448
Long term debt to equity
23.504
Total debt to equity
23.504
Interest coverage (TTM)
-9.76%
Management effectiveness
Return on assets (TTM)
-7.74%
Return on equity (TTM)
-26.10%
Valuation
Price to revenue (TTM)
20.047
Price to book
11.66
Price to tangible book (TTM)
23.4
Price to free cash flow (TTM)
-88.885
Growth
Revenue change (TTM)
18.70%
Earnings per share change (TTM)
8.83%
3-year revenue growth (CAGR)
7.02%
3-year earnings per share growth (CAGR)
51.95%
What the Analysts think about Glaukos
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Glaukos stock.
Glaukos Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Glaukos Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Glaukos News
AllArticlesVideos
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Benzinga·2 weeks ago
Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Glaukos stock?
Glaukos (GKOS) has a market cap of $7.8B as of November 22, 2024.
What is the P/E ratio for Glaukos stock?
The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of November 22, 2024.
Does Glaukos stock pay dividends?
No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Glaukos dividend payment date?
Glaukos (GKOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Glaukos?
Glaukos (GKOS) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.